BACKGROUND

Existing research has shown that long non-coding RNA (lncRNA) MAGI2 antisense RNA3 (MAGI2-AS3) expression is significantly decreased in breast cancer tissues and can inhibit breast cancer progression. However, the relationship between MAGI2-AS3 expression levels in peripheral blood mononuclear cells (PBMCs) and breast cancer remains unclear. This study aimed to explore the clinical significance of MAGI2-AS3 expression in PBMCs for diagnosing breast cancer and predicting patient prognosis.

METHODS

Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to detect MAGI2-AS3 expression in PBMCs from healthy donors and breast cancer patients. The chi-square test analyzed the associations between MAGI2-AS3 expression and breast cancer clinicopathological parameters. The Kaplan-Meier method evaluated the impact of MAGI2-AS3 on patients' overall survival (OS), and receiver operating characteristic (ROC) analysis assessed its diagnostic accuracy for breast cancer.

RESULTS

MAGI2-AS3 expression was significantly downregulated in breast cancer patients' PBMCs compared to the control group. Its expression decreased with the advancement of tumor-node-metastasis (TNM) stage and elevation of pathological grade, and was remarkably lower in patients with distant metastasis (DM). Low MAGI2-AS3 expression in PBMCs was correlated with shorter OS. ROC curve analysis showed that MAGI2-AS3 in PBMCs had good diagnostic accuracy.

CONCLUSION

MAGI2-AS3 expression in breast cancer patients' PBMCs is reduced and negatively correlated with patient outcomes. Thus, it has the potential to be a valuable biomarker for breast cancer diagnosis and prognostic evaluation.